Trilaciclib plus mFOLFIRINOX for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug, trilaciclib, combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if adding trilaciclib can help reduce side effects and improve how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are able to care for yourself and do daily activities (ECOG 0-1).
- You have been diagnosed with advanced pancreatic cancer (confirmed by biopsy).
- You have not received any cancer treatment before for this cancer.
- Your blood counts (white cells, red cells, platelets) and kidney/liver function are within safe ranges.
- You agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This Phase 2 study tests whether FOLFIRINOX given after pancreatic surgery can lower the chance the cancer comes back. It focuses on people with pancreatic ductal adenocarcinoma who had their tumor completely removed and have no spread to distant organs.
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
This trial tests a stronger version of FOLFIRINOX chemotherapy for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. It aims to see if the new dosing schedule works better and is safe.
This trial tests whether giving a strong chemotherapy combination (mFOLFIRINOX) together with radiation therapy can help people with advanced pancreatic cancer who have normal CA19-9 levels. It aims to see if this approach is more effective for this specific group of patients.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.